Spyre Therapeutics Inc was acquired by Aeglea BioTherapeutics in June 2023, shifting focus to developing antibody therapeutics for inflammatory bowel disease (IBD). The company targets IBD patients, including those with ulcerative colitis and Crohn's disease.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.